# Yooyoung Pharmaceutical Co., Ltd. clinical trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Yooyoung Pharmaceutical Co., Ltd. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Yooyoung Pharmaceutical Co., Ltd.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/yooyoung-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 31, 2025 | NCT07096050 | Post Marketing Clinical Follow up Study of HyaleXo | Yooyoung Pharmaceutical Co., Ltd. | Not applicable | Completed | Knee Osteoarthritis | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07096050) |
| May 5, 2022 | NCT05362851 | Clinical Trial of YYC301 P3 for Treatment of Osteoarthritis of the Knee | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Osteoarthritis, Knee | 692 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05362851) |
| April 27, 2022 | NCT05348525 | Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUS | Yooyoung Pharmaceutical Co., Ltd. | Observational | Unknown | Osteoarthritis, Knee, Degenerative Joint Disease of Knee | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05348525) |
| February 8, 2022 | NCT05229458 | Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of HYALEXO | Yooyoung Pharmaceutical Co., Ltd. | Observational | Unknown | Osteoarthritis, Degenerative Joint Disease | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05229458) |
| February 7, 2022 | NCT05226897 | Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Type 2 Diabetes | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05226897) |
| May 5, 2021 | NCT04874142 | Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A | Yooyoung Pharmaceutical Co., Ltd. | Phase 1 | Completed | Dyslipidemias | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04874142) |
| May 5, 2021 | NCT04874129 | Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506 | Yooyoung Pharmaceutical Co., Ltd. | Phase 1 | Unknown | Dyslipidemias | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04874129) |
| April 26, 2021 | NCT04858308 | Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506. | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Dyslipidemias | 554 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04858308) |
| June 13, 2019 | NCT03985319 | Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1) | Yooyoung Pharmaceutical Co., Ltd. | Phase 1 | Completed | GERD | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03985319) |
| May 30, 2019 | NCT03967886 | Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Completed | Non-erosive Reflux Disease | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03967886) |
| May 9, 2019 | NCT03943992 | Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD) | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Completed | Erosive Esophagitis | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03943992) |
| February 22, 2019 | NCT03850587 | Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee | Yooyoung Pharmaceutical Co., Ltd. | Phase 2 | Completed | Osteoarthritis, Knee | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03850587) |
| June 19, 2018 | NCT03561779 | Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Completed | Osteoarthritis, Knee | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03561779) |
| June 15, 2018 | NCT03558477 | PK/PD Clinical Trial of YYD601 in Healthy Adult Male | Yooyoung Pharmaceutical Co., Ltd. | Phase 1 | Completed | GERD | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03558477) |
| June 13, 2018 | NCT03555123 | Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Acute Decompensated Heart Failure | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03555123) |
| July 11, 2017 | NCT03214211 | Prospective Observational Study of Pravafenix Cap | Yooyoung Pharmaceutical Co., Ltd. | Observational | Unknown | Dyslipidemias | 3,088 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03214211) |
| May 30, 2017 | NCT03170050 | Clinical Trial of YYD701-2 for Treatment of Nasolabial Folds | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Completed | Wrinkle Severity Rating Scale(WSRS) Grade 3 (Moderate) or 4 (Severe) of Nasolabial Folds | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03170050) |
| November 16, 2016 | NCT02965495 | Clinical Trial of YYD302 for Treatment of Osteoarthritis of the Knee | Yooyoung Pharmaceutical Co., Ltd. | Phase 1/2 | Completed | Osteoarthritis, Knee | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02965495) |
| September 18, 2015 | NCT02554552 | Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee | Yooyoung Pharmaceutical Co., Ltd. | Phase 1/2 | Withdrawn | Osteoarthritis, Knee | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02554552) |
| March 6, 2015 | NCT02382159 | A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes. | Yooyoung Pharmaceutical Co., Ltd. | Observational | Completed | Complex Dyslipidemia | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02382159) |
| June 18, 2014 | NCT02166593 | Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 | Completed | Combined Dyslipidemia | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02166593) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 3 | 9 |
| Not applicable | 1 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Unknown | 8 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Osteoarthritis, Knee | 7 |
| Osteoarthritis | 4 |
| Dyslipidemias | 4 |
| Gastroesophageal Reflux | 2 |
| Diabetes Mellitus, Type 2 | 1 |
| Joint Diseases | 1 |
| Lymphoma, Follicular | 1 |
| Non-Erosive Reflux Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Oncology practices in the United States](https://specstream.ai/data/businesses/oncology-practices/united-states)
- [Pediatric clinics in the United States](https://specstream.ai/data/businesses/pediatric-clinics/united-states)
- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
- [Public adjusters in the United States](https://specstream.ai/data/businesses/public-adjusters/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
